<DOC>
	<DOCNO>NCT01773733</DOCNO>
	<brief_summary>The aim study summarize data efficacy safety Reduxine administration routine clinical practice accord approve indication .</brief_summary>
	<brief_title>The PRIMAVERA Study : Reduxine Safety Monitoring Patients With Alimentary Obesity</brief_title>
	<detailed_description>Secondary objective : - study structure population patient diet induced obesity body mass index ( BMI ) 30 kg/m2 diet induced obesity BMI ≥27 kg/m2 associate type 2 diabetes mellitus respect comorbidities concomitant treatment determine area investigation . - introduce element control adverse cardiovascular risk routine clinical practice : questionnaire concern enrollment criterion Reduxine treatment initiation , algorithm Reduxine administration treatment efficacy safety monitoring ( assessment schedule ) . - assess effect treatment overweight obesity Reduxine patient ' quality life parameter . The Time Frame : follow study patient perform six month one year . Exception - premature discontinuation study . The scheduled visit patient investigational centre : Week0 ( inclusion patient ) , Week 2 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 36 Week 48 .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Men woman 1865 year age , doctor 's opinion , onlabel use Reduxine indicate . Patient 's desire ability participate program fulfill doctor 's instruction design achieve treatment goal program requirement compliance . Signed informed consent form participation program . Patients age 18 old 65 ; Current history : coronary artery disease ( e.g . angina , myocardial infraction ) ; congestive heart failure ; tachycardia ; peripheral arterial occlusive disease ; arrythmia ; Uncontrolled arterial hypertension &gt; 145/90 mm Hg ; Hypersensitivity sibutramine component Reduxine® ; Current use monoamineoxidase inhibitor ( IMAO ) use within last 2 week ; Current use central act weight reduce drug use within last 2 week ; Use drug affect central nervous system ( e.g . antidepressant , neuroleptic ) ; tryptophancontaining drug indicate sleep disturbance ; Severe eat disorder ( anorexia nervosa bulimia ) ; Mental disease ; Gilles de la Tourette syndrome ( generalized tic ) ; Body mass index ≤30 kg/m2 ≤27 kg/m2 presence concomitant disease ( dyslipidemia , diabetes ) ; Organic cause obesity ( e.g . hypothyrosis ) ; Thyrotoxicosis ; Sever liver and/or kidney function abnormality ; Benign prostatic hyperplasia ; Phaeochromocytoma ; Narrowangle glaucoma ; Documented pharmacologic , drug alcohol addiction ; Pregnancy lactation ; Refusal sign inform consent form participation program ; Participation clinical study new drug product within 90 day prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>